Detail of "155206-00-1"

CAS Number:
155206-00-1
Name:
Bimatoprost
Molecular Structure:
Formula:
C₂₅H₃₇NO₄
Molecular Weight:
415.57
Deleted CAS:
267244-98-4
Synonyms:
AGN 192024;5-Heptenamide,7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-, (5Z)-;Lumigan;Prostamide;
Density:
1.145 g/cm³
Boiling Point:
629.8 ºC at 760 mmHg
Flash Point:
334.7 ºC
Solubility:
very soluble in ethyl alcohol and methyl alcohol and slightly soluble in water
Appearance:
crystalline solid

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

All Suppliers

Page：1/2

Supplier Location
Supplier Location
- China (Mainland)(39)
- United States(6)
- Denmark(2)
- India(2)
- Switzerland(2)
- China(Taiwan)(1)
Business Type
Business Type
- Lab/Research institutions(16)
- Manufacturers(1)
- Other(1)
- Trading Company(33)
Certificates
Certificates
- ISO(1)
- Production License(1)

Please post your buying leads>>

Display：

Manufacturer
Enterprise Authentication
Suppiers of more reward points first
New supplier

CAS No.155206-00-1 Bimatoprost

Supplier:Taizhou Crene Biotechnology co.ltd[ China (Mainland)]

Verified-Platinum Supplier 1st Year Platinum
Supplier 1090 Integral
1090

Contact:Mr. Rene

Tel:86-576-88813233 88205808

Fax:86-576-88229589

Address:Economic Developed Zone of Taizhou Zhejiang China

Contact Suppliers

Total:53 Page 1 of 2 1 2 Next>>

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

Comparing bimatoprost and travoprost in black Americans: All Rights Reserved. Comparing bimatoprost and travoprost in black Americans. Noecker, Robert J.; Earl, Melissa L.; Mundorf, Thomas K.; Silverstein, Steven M.; Phillips, Michael P. (Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA). Current Medical Research and Opinion, 22(11), 2175-2180 (English) 2006 LibraPharm Ltd. CODEN: CMROCX. ISSN: 0300-7995. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Objective: To compare the intraocular pressure-lowering efficacy and safety of topical bimatoprost 0. 157283-68-6 and 155206-00-1 are cas registry numbers. These chemicals are also mentioned in this article.03% with that of travoprost 0.004% for the treatment of black patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). Research design and methods: Multicenter, prospective, randomized, investigator-masked trial of 94 black patients previously diagnosed with OAG or OHT. All patients completed washout of ocular hypotensive medications before study participation. Patients were assigned to either once-daily bimatoprost 0.03% or once-daily travoprost 0.004% for 3 mo. Main outcome measures: The primary outcome measures were mean intraocular pressure (IOP), mean change from baseline IOP, and percentage of patients who reached a target IOP redn. Secondary measures included ophthalmol. examn. and adverse events. Results: Both bimatoprost and travoprost significantly lowered IOP at all study visits (p < 0.001). Bimatoprost provided mean IOP redns. from baseline that ranged from 6.8 mmHg to 7.8 mmHg (27% to 31%). Travoprost provided mean IOP redns. from baseline that ranged from 6.2 mmHg to 6.9 mmHg (25% to 28%). By month 3, 85% of participants in the bimatoprost group had a mean IOP redn. of at least 20%, compared with 68% of those in the travoprost group. Furthermore, 31.9% of those in the bimatoprost group had a mean IOP redn. of more than 40% at month 3 compared with 20.9% of those in the travoprost group. There were no significant differences in biomicroscopy, ophthalmoscopy, or visual acuity. Ocular redness was the most commonly reported adverse event in both treatment groups. No serious adverse events were reported. Conclusions: Bimatoprost and travoprost each effectively lowered IOP in this population of black patients. More patients achieved clin. relevant IOP redns. with bimatoprost. .

Bimatoprost: A novel antiglaucoma agent: Bimatoprost: A novel antiglaucoma agent. Woodward, D. F.; Phelps, R. L.; Krauss, A. H-P.; Weber, A.; Short, B.; Chen, J.; Liang, Y.; Wheeler, L. A. (Department of Biological Sciences, Allergan Inc., Irvine, CA, USA). Cardiovascular Drug Reviews, 22(2), 103-120 (English) 2004 Neva Press. CODEN: CDREEA. ISSN: 0897-5957. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. The aim of glaucoma therapy is to preserve vision by reducing intraocular pressure (IOP). Following recent National Eye Institute sponsored studies, it is becoming increasingly apparent that every mmHg of extra IOP lowering counts. Bimatoprost is the newest and most effective addn. 155206-00-1 is the cas registry number of certain chemical which is used as reagents here. to the physician's armamentarium of ocular hypotensive drugs. Direct clin. comparisons have demonstrated that it is more efficacious than the prostaglandin (PG) FP receptor agonist prodrugs, latanoprost and travoprost, as well as a b-adrenoceptor antagonist, timolol, alone or in fixed combination with the carbonic anhydrase inhibitor, dorzolamide. Moreover, patients that are refractory to latanoprost therapy may be successfully treated with bimatoprost. Such evidence provides support, at the clin. level, for the contention that bimatoprost is pharmacol. distinct from PG FP receptor agonist prodrugs. Bimatoprost is a structural analog of PGF2a-ethanolamide (prostamide F2a), which is formed from the endocannabinoid anandamide by a biosynthetic pathway involving cyclooxygenase-2 (COX-2). Their pharmacol. is remarkably similar, such that bimatoprost may be regarded as a prostamide mimetic. The target receptor for bimatoprost and the prostamides appears unique and unrelated to PG- and endocannabinoid-sensitive receptors. Extensive ocular distribution/metab. studies in non-human primates demonstrate that bimatoprost is not a prodrug, it remains essentially intact. Its profound ocular hypotensive effects may, therefore, be attributed to its prostamide-mimetic properties. .

Detail of "155206-00-1"

Bimatoprost

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

CAS No.155206-00-1 Bimatoprost

Reference